Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years

Vaccine

Volumn 33, Issue 46, 2015, Pages 6264-6267

  Petráš, Marek ^a   Adámková, Věra ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Genital warts; Human papillomavirus; Immunisation; Quadrivalent vaccine; Recurrence

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; CROSS-SECTIONAL STUDY; CZECH REPUBLIC; FEMALE; HEALTH CARE SURVEY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRIORITY JOURNAL; SEXUALITY; WART VIRUS; CONDYLOMATA ACUMINATA; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; CONDYLOMATA ACUMINATA; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; RISK ASSESSMENT; YOUNG ADULT;

EID: 84947031652     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.071     Document Type: Article

References (22)

1. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001, 11:598-603.
2. Munk C., Nielsen A., Liaw K.L., Kjaer S.K. Genital warts in men: a large population-based cross-sectional survey of Danish men. Sex Transm Infect 2012, 88:640-644.
3. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196:1447-1454.
4. Dinh T.H., Sternberg M., Dunne E.F., Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008, 35:357-360.
5. Clarke P., Ebel C., Catotti D.N., Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996, 7:197-200.
6. Maw R.D., Reitano M., Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998, 9:571-578.
7. Kodner C.M., Nasraty S. Management of genital warts. Am Fam Physician 2004, 70:2335-2342.
8. FUTURE I.I.Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 2007, 356:1915-1927.
9. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 2007, 356:1928-1943.
10. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
11. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372:711-723.
12. Ali H., Donovan B., Wand H., Read T.R., Regan D.G., Grulich A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
13. Blomberg M., Dehlendorff C., Munk C., Kjaer S.K. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013, 57:929-934.
14. Mariani L., Vici P., Suligoi B., Checcucci-Lisi G., Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015, 32:10-30.
15. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
16. Petráš M., Adámková V. Rates and predictors of genital warts burden in the Czech population. Int J Infect Dis. 2015, 35:29-33.
17. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccine 2009, 5:696-704.
18. Muñoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
19. ® 2011, (Abstract SS 19-6).
20. Szarewski A., Skinner S.R., Garland S.M., Romanowski B., Schwarz T.F., Apter D., et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis 2013, 208:1391-1396.
21. von Krogh G., Lacey C.J., Gross G., Barrasso R., Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001, 12(Suppl 3):40-47.
22. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A., et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012, 344:e1401. FUTURE I and II Study Group.